Bio Medica Laboratories Ltd IPO

Designing and execution capabilities.

Experienced management team and a motivated and efficient work force.

Cordial relations with our consumers.

Quality assurance and control.

The operations in the company Manufacturing Unit-1 had been suspended vide order No. V/T/MISC/20/2023/4790 dated August 23, 2023 by the Deputy Director and State Licensing Authority, Food and Drug Administration, Madhya Pradesh citing certain non-compliances.

The company is dependent on a limited number of clients for a significant portion of its revenues, and the loss of any key client could adversely affect the company business, financial condition and results of operations.

Any manufacturing or quality control problems may damage the company reputation for high quality products and expose its to litigation or other liabilities, which could adversely affect the company financial results.

The Companys manufacturing facilities are subject to inspections by the Central Drugs Standard Control Organisation (CDSCO), the State Licensing Authorities, and other competent regulatory bodies. Any adverse findings or non-compliance may result in regulatory actions that could adversely affect the Companys business, operations, and financial performance

The company is dependent on third-party transportation providers for the supply of raw materials and finished products

The company inability to adopt new technologies could adversely affect its business, results of operations, cash flows and financial condition.

The Contracts in the company order book may be adjusted, cancelled, or suspended by its clients at their discretion, and therefore the company order book is not necessarily indicative of future revenues or earnings.

The company existing manufacturing facilities are concentrated in a single region i.e., Industrial Area, Indore, Madhya Pradesh and the inability to operates and grow its business in this particular region may have an adverse effect on the company business, financial condition, results of operations, cash flows and future business prospects.

The Company has negative cash flows from its investment and financing activities in the current and past years. Sustained negative cash flow could have an impact on the company growth and business.

The Company has had a high debt-to-equity ratio in previous financial years, and although this has improved in FY 2025, there can be no assurance that its will be able to maintain such levels going forward, which may affect the company ability to meet obligations and pursue growth opportunities.